DRAGEN TruSight Oncology 500 v2.5.2 is now available. Performance updates include extended small variant calling, expanded CNV calling and a new sex prediction algorithm.
TruSight Oncology 500 High-Throughput
Enabling comprehensive genomic profiling from FFPE samples, with added flexibility to batch up to 192 samples per flow cell.
Read More...
This product is only available in select locations. Please select the location where you would like this product to be shipped to see availability.
Manual Prep
Automation
Price
Index Adapters
Reagents
Services
Software and Informatics Options
Illumina Connected Insights-Annual Subscription
20090137
Illumina Connected Insights‒Oncology Genome Equivalent Sample-VCF
20090138
Illumina Connected Insights‒Training and Onboarding
20092376
Informatics Professional Services
20071787
Total:
Product Highlights
The TruSight Oncology 500 High-Throughput assay is built on the foundation of the TruSight Oncology 500 assay, with flexibility for higher sample throughput and batching options.
Consolidate Multiple Biomarker Assays into One
- Pan-cancer biomarker content aligned with key guidelines and clinical trials
- 523 genes for assessment of all DNA and RNA variant types, plus microsatellite instability (MSI) and tumor mutational burden (TMB)
- Increase chances of finding a positive biomarker by moving from individual biomarker assays to a single comprehensive NGS assay
Streamlined Sample-to-Results Workflow
- Go from initial sample to results in 4-5 days
- Rapid variant calling algorithm powered by DRAGEN pipelines, available locally on DRAGEN server
- Secure, scalable, cloud-based variant calling is available with DRAGEN pipelines on Illumina Connected Analytics (ICA) featuring auto-launch capability.
- Multiple verified tertiary analysis options available, including Illumina Connected Insights‡ and Pierian Clinical Genomics Workspace
High Sample Throughput
- Flexible sample batching allows you to run anywhere from 16 to 192 samples per sequencing flow cell on the NovaSeq 6000 or NovaSeq 6000Dx System in RUO Mode†
Achieve Highly Confident Results
- Hybrid-capture chemistry combined with sophisticated bioinformatics, leading to high analytical specificity and sensitivity
- Inclusive of unique molecular indexes (UMIs) for high sensitivity in variant detection
- Based on proven Illumina SBS sequencing technology
Enable In-House Comprehensive Genomic Profiling
- Keep samples and data in house, for more control and ability to build a database
- A future-proof assay with emerging biomarkers already included
Automation
Automation is available on the Beckman Coulter i-Series or the Hamilton Microlab STAR.
†NovaSeq 6000Dx System in RUO Mode requires a separate, stand-alone DRAGEN server for secondary analysis.
‡Not available in all countries. Illumina Connected Insights supports user-defined tertiary analysis through API calls to third-party knowledge sources.
TruSight Oncology 500 Portfolio
All three TruSight Oncology 500 assays are designed to identify key biomarkers in guidelines and clinical trials.
TruSight Oncology 500 Assay
Assess key cancer biomarkers from FFPE tumor tissue with the TruSight Oncology 500 Assay.
TruSight Oncology 500 High-Throughput Assay
Batch up to 192 samples at a time while using the same biomarkers and tissue type as the TruSight Oncology 500 assay.
TruSight Oncology 500 ctDNA Assay
Analyze circulating tumor DNA from plasma with the TruSight Oncology 500 ctDNA assay.
Interested in learning more about the TSO 500 portfolio of products? Download the overview brochure.
Frequently Purchased Together
Specifications
Product Comparison
| TruSight Oncology 500 High-Throughput | TruSight Oncology 500 | TruSight Oncology 500 ctDNA v2 | |
|---|---|---|---|
| Cancer Type | Pan-Cancer | Pan-Cancer | Pan-Cancer, Solid Tumor |
| Content Specifications | Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size. • Immuno-oncology Biomarker Coverage: TMB and MSI • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Clinical Trials Coverage: Over 600 clinical trials* |
||
| Hands-On Time | Manual: ~10.5 hrs Automated: ~2.5 hrs |
Manual: ~10.5 hrs Automated: ~2.5 hrs (TruSight Oncology 500 only), Manual: ~10.5 hrs Automated: ~2.5 hrs (TruSight Oncology 500 only) |
|
| Input Quantity | 40 ng DNA, 40-80 ng RNA (need at least 2 mm3 FFPE tissue) | 40 ng DNA, 40 ng RNA | |
| Method | Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing | Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing | Target Enrichment, Target Enrichment, Targeted DNA Sequencing |
| Nucleic Acid Type | RNA, DNA | RNA, DNA | DNA |
| Sample Throughput | 16–192 samples per flow cell | ||
| Specialized Sample Types | FFPE Tissue | FFPE Tissue | Blood, Circulating Tumor DNA |
| Species Category | Human | Human | Human |
| System Compatibility | NovaSeq 6000, NovaSeq 6000Dx in Research Mode | NextSeq 500, NextSeq 550, NextSeq 550Dx in Research Mode | NovaSeq 6000 |
| Technology | Sequencing | Sequencing | Sequencing |
| Variant Class | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants | Copy Number Variants (CNVs), Insertions-Deletions (indels), Single Nucleotide Variants (SNVs) |
| Variant Class Details | For TruSight Oncology 500 HRD, genomic instability score, and the following beta features - tumor fraction, tumor ploidy, absolute copy number, and gene-level loss of heterozygosity - are available. Beta features have not been verified by Illumina. See the v2.5+ customer release notes for more details. | For TruSight Oncology 500 HRD, genomic instability score, and the following beta features - tumor fraction, tumor ploidy, absolute copy number, and gene-level loss of heterozygosity - are available. Beta features have not been verified by Illumina. See the v2.5+ customer release notes for more details. |
* Based on Velsera clinical knowledgebase, as of February 2023.
† NovaSeq 6000Dx System in RUO Mode requires a separate, stand-alone DRAGEN server for secondary analysis.
High concordance of TMB status between DRAGEN TruSight Oncology v2 and Local App
High concordance of MSI status between DRAGEN TruSight Oncology v2 and Local App
High concordance of CNV (Gene Amplification) detection between DRAGEN TruSight Oncology v2 and Local App
High concordance of SNVs with mean VAF >5% between DRAGEN TruSight Oncology v2 and Local App
Robust detection of fusions and splice variants
Fusion and splice variants as detected using TruSight Oncology 500 o the NextSeq 500 System. Numeric values represent the number of supporting reads for each sample at the indicated RNA input amount. Cut-off value for RNA fusions = 5; cut-off value for splice variants = 10.
Comprehensive genomic profiling including all main variant types – exon-level CNVs now included for BRCA1/2!
DRAGEN brings speed to TruSight Oncology 500 secondary analysis
Product Literature
Simplifying the process to identify applicable variants in oncology samples
Brochure | PDF 2 MB
Optimizing RNA input to detect gene fusions with TruSight Oncology 500 High-Throughput
Technical Note | PDF < 1 MB
Data analysis and reporting for the TruSight Oncology 500 portfolio
Product Information Sheet | PDF 1 MB
Simply better variant calling with DRAGEN analysis
Product Information Sheet | PDF < 1 MB
Automating TruSight Oncology 500 High-Throughput
Technical Note | PDF < 1 MB
Data Sheet | PDF | 7 versions
Manuals and Support Information
DRAGEN TruSight Oncology 500 Analysis Software v2.5.2 Documentation
TruSight Oncology 500 v2.0 Local App Documentation
TruSight Oncology 500 High Throughput Consumables & Equipment Documentation
DRAGEN TruSight Oncology 500 Analysis Software v1.1 Documentation
TruSight Oncology 500 v1.0 Local App Documentation
TruSight Oncology 500 v2.1 Local App Documentation
DRAGEN TruSight Oncology 500 Analysis Software v2.1 Documentation
TruSight Oncology 500 High Throughput Reference Guide Documentation
DRAGEN TruSight Oncology 500 Analysis Software v2.1.2 on ICA Documentation
DRAGEN TruSight Oncology 500 Analysis Software v1.1 on ICA Documentation
TruSight Oncology 500 High Throughput Checklist Documentation
TruSight Oncology 500 v2.2 Local App Documentation
DRAGEN TruSight Oncology 500 Analysis Software v2.5.2 on ICA Documentation
Custom Protocol Selector
Generates customized, end-to-end instructions
Illumina DNA PCR-Free Prep
A high-performing, fast, and integrated workflow for sensitive applications such as human whole-genome sequencing.
NovaSeq 6000 Reagent Kits
Reagent kits for the NovaSeq 6000 system provide ready-to-use cartridge-based reagents for cluster generation and SBS.
TruSight Oncology 500 ctDNA v2
Enable CGP with a pan-cancer panel capable of detecting key IO gene signatures (TMB, MSI) plus all main variant classes from ctDNA in blood plasma.
TruSight Oncology 500
Assay targeting multiple variant types, including microsatellite instability (MSI) and tumor mutational burden (TMB).